StreetInsider.com News Articles

Lifecore Biomedical signs manufacturing deal for neurology product

Mon, 15 Jun 2026 07:05:11 -0400

Lifecore Biomedical Inc. (NASDAQ: LFCR) announced it signed an agreement with an unnamed global pharmaceutical company to provide technical transfer services and commercial manufacturing for an injectable suspension product treating neurological disorders.

The Chaska, Minnesota-based contract development and manufacturing organization will handle production of the higher-viscosity suspension formulation for the currently marketed neurology product. The company said this marks its seventh late-stage program agreement in seven months.

"Being selected to produce this higher-viscosity suspension formulation demonstrates confidence in Lifecore's technical know-how and exceptional quality track record," said Paul Josephs, chief executive officer of Lifecore, according to the press release.

Lifecore specializes in sterile

Lifecore Biomedical signs manufacturing deal for neurology product

Mon, 15 Jun 2026 07:05:11 -0400

Lifecore specializes in sterile

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

Mon, 15 Jun 2026 07:05:00 -0400

--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product--

--Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months--

CHASKA, Minn., June 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced it has signed a new agreement with a global pharmaceutical company. Under the terms of the agreement, Lifecore will perform technical transfer services to support the commercial production of an injectable suspension product for neurological disorders.

“With this significant new customer win, we have

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

Mon, 15 Jun 2026 07:05:00 -0400

--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product--

--Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months--

“With this significant new customer win, we have

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

Mon, 15 Jun 2026 07:05:00 -0400

--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product--

--Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months--

“With this significant new customer win, we have

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

Mon, 15 Jun 2026 07:05:00 -0400

--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product--

--Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months--

“With this significant new customer win, we have

Form 4 LIFECORE BIOMEDICAL, For: Jun 04 Filed by: Legion Partners Holdings, LLC

Mon, 08 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260608/26617939.html

Form 4 LIFECORE BIOMEDICAL, For: Jun 04 Filed by: Legion Partners Holdings, LLC

Mon, 08 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260608/26617939.html

Form 4 LIFECORE BIOMEDICAL, For: Jun 04 Filed by: OBUS NELSON

Fri, 05 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260605/26611876.html

Form 4 LIFECORE BIOMEDICAL, For: Jun 04 Filed by: OBUS NELSON

Fri, 05 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260605/26611876.html

Form 4 LIFECORE BIOMEDICAL, For: Jun 04 Filed by: Korenberg Matthew E